IL152426A - A DNA transfection system to form an infectious negative-strand RNA virus - Google Patents
A DNA transfection system to form an infectious negative-strand RNA virusInfo
- Publication number
- IL152426A IL152426A IL152426A IL15242601A IL152426A IL 152426 A IL152426 A IL 152426A IL 152426 A IL152426 A IL 152426A IL 15242601 A IL15242601 A IL 15242601A IL 152426 A IL152426 A IL 152426A
- Authority
- IL
- Israel
- Prior art keywords
- virus
- plasmid
- rna
- pol
- viral
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 326
- 208000015181 infectious disease Diseases 0.000 title claims description 75
- 230000002458 infectious effect Effects 0.000 title claims description 58
- 108020004414 DNA Proteins 0.000 title description 84
- 238000001890 transfection Methods 0.000 title description 75
- 239000013612 plasmid Substances 0.000 claims abstract description 248
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 230
- 230000003612 virological effect Effects 0.000 claims abstract description 140
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 claims abstract description 118
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 claims abstract description 118
- 241001493065 dsRNA viruses Species 0.000 claims abstract description 96
- 229960005486 vaccine Drugs 0.000 claims abstract description 75
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 54
- 238000004519 manufacturing process Methods 0.000 claims abstract description 50
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 43
- 230000002238 attenuated effect Effects 0.000 claims abstract description 42
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 39
- 102000005348 Neuraminidase Human genes 0.000 claims abstract description 34
- 108010006232 Neuraminidase Proteins 0.000 claims abstract description 34
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract description 28
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract description 28
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract description 28
- 101710176177 Protein A56 Proteins 0.000 claims abstract description 28
- 239000000185 hemagglutinin Substances 0.000 claims abstract description 27
- 210000004027 cell Anatomy 0.000 claims description 220
- 102000004169 proteins and genes Human genes 0.000 claims description 117
- 238000013518 transcription Methods 0.000 claims description 112
- 239000002299 complementary DNA Substances 0.000 claims description 111
- 230000035897 transcription Effects 0.000 claims description 107
- 108020004999 messenger RNA Proteins 0.000 claims description 102
- 238000000034 method Methods 0.000 claims description 57
- 241000712431 Influenza A virus Species 0.000 claims description 53
- 108010067390 Viral Proteins Proteins 0.000 claims description 38
- 206010022000 influenza Diseases 0.000 claims description 32
- 108700007698 Genetic Terminator Regions Proteins 0.000 claims description 31
- 230000002457 bidirectional effect Effects 0.000 claims description 31
- 230000008488 polyadenylation Effects 0.000 claims description 21
- 238000004113 cell culture Methods 0.000 claims description 20
- 230000001717 pathogenic effect Effects 0.000 claims description 20
- 241000713196 Influenza B virus Species 0.000 claims description 14
- 101710177611 DNA polymerase II large subunit Proteins 0.000 claims description 13
- 101710184669 DNA polymerase II small subunit Proteins 0.000 claims description 13
- 108010013845 RNA Polymerase I Proteins 0.000 claims description 13
- 102000017143 RNA Polymerase I Human genes 0.000 claims description 13
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 210000003501 vero cell Anatomy 0.000 claims description 8
- 102000053642 Catalytic RNA Human genes 0.000 claims description 6
- 108090000994 Catalytic RNA Proteins 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 108091092562 ribozyme Proteins 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 5
- 101150076514 NS gene Proteins 0.000 claims description 4
- 101150039660 HA gene Proteins 0.000 claims description 3
- 101710085938 Matrix protein Proteins 0.000 claims description 3
- 101710127721 Membrane protein Proteins 0.000 claims description 3
- 101150080862 NA gene Proteins 0.000 claims description 3
- 108010009460 RNA Polymerase II Proteins 0.000 claims description 3
- 102000009572 RNA Polymerase II Human genes 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 101150118742 NP gene Proteins 0.000 claims description 2
- 101150105115 PA gene Proteins 0.000 claims description 2
- 101150030427 PB2 gene Proteins 0.000 claims description 2
- 241000831652 Salinivibrio sharmensis Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 108091034135 Vault RNA Proteins 0.000 claims 3
- 101150084750 1 gene Proteins 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 168
- 108020000999 Viral RNA Proteins 0.000 abstract description 73
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract description 46
- 108091007433 antigens Proteins 0.000 abstract description 19
- 102000036639 antigens Human genes 0.000 abstract description 19
- 239000000427 antigen Substances 0.000 abstract description 18
- 238000011161 development Methods 0.000 abstract description 17
- 230000009977 dual effect Effects 0.000 abstract description 13
- 230000003834 intracellular effect Effects 0.000 abstract description 9
- 238000002255 vaccination Methods 0.000 abstract description 9
- 102000012750 Membrane Glycoproteins Human genes 0.000 abstract 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 59
- 239000013613 expression plasmid Substances 0.000 description 48
- 239000002245 particle Substances 0.000 description 34
- 210000002845 virion Anatomy 0.000 description 32
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 26
- 239000006228 supernatant Substances 0.000 description 26
- 239000013598 vector Substances 0.000 description 26
- 230000010076 replication Effects 0.000 description 25
- 108020004635 Complementary DNA Proteins 0.000 description 24
- 208000037797 influenza A Diseases 0.000 description 24
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 23
- 238000010240 RT-PCR analysis Methods 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 102100037516 Protein polybromo-1 Human genes 0.000 description 20
- 101710085035 RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 20
- 102000039446 nucleic acids Human genes 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- 102000011931 Nucleoproteins Human genes 0.000 description 18
- 108010061100 Nucleoproteins Proteins 0.000 description 18
- 108700005077 Viral Genes Proteins 0.000 description 18
- 238000011084 recovery Methods 0.000 description 18
- 230000001413 cellular effect Effects 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 101710102873 Polymerase basic protein 2 Proteins 0.000 description 16
- 241000702670 Rotavirus Species 0.000 description 16
- 239000002671 adjuvant Substances 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 230000018109 developmental process Effects 0.000 description 16
- 235000013601 eggs Nutrition 0.000 description 16
- 230000012010 growth Effects 0.000 description 16
- 230000014616 translation Effects 0.000 description 16
- 238000011144 upstream manufacturing Methods 0.000 description 16
- 108091026890 Coding region Proteins 0.000 description 15
- 238000013459 approach Methods 0.000 description 15
- 238000010367 cloning Methods 0.000 description 15
- 230000028993 immune response Effects 0.000 description 15
- 108091092724 Noncoding DNA Proteins 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 238000013519 translation Methods 0.000 description 14
- 230000003321 amplification Effects 0.000 description 13
- 210000004443 dendritic cell Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 208000037798 influenza B Diseases 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- 102000004389 Ribonucleoproteins Human genes 0.000 description 12
- 108010081734 Ribonucleoproteins Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 101150113162 pbl gene Proteins 0.000 description 12
- 230000001681 protective effect Effects 0.000 description 12
- 239000013599 cloning vector Substances 0.000 description 11
- 238000010276 construction Methods 0.000 description 11
- 210000004940 nucleus Anatomy 0.000 description 11
- 108090000288 Glycoproteins Proteins 0.000 description 10
- 108700026244 Open Reading Frames Proteins 0.000 description 10
- 101710172711 Structural protein Proteins 0.000 description 10
- 101710137500 T7 RNA polymerase Proteins 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 230000000890 antigenic effect Effects 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 10
- 229960003971 influenza vaccine Drugs 0.000 description 10
- 230000000977 initiatory effect Effects 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000003886 Glycoproteins Human genes 0.000 description 9
- 241000711513 Mononegavirales Species 0.000 description 9
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 9
- -1 pol HI Proteins 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 239000012124 Opti-MEM Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000029812 viral genome replication Effects 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 7
- 108060004795 Methyltransferase Proteins 0.000 description 7
- 241000712464 Orthomyxoviridae Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 108010006025 bovine growth hormone Proteins 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 241000702247 Reoviridae Species 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 102000009016 Cholera Toxin Human genes 0.000 description 5
- 108010049048 Cholera Toxin Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 102100031780 Endonuclease Human genes 0.000 description 5
- 101710144128 Non-structural protein 2 Proteins 0.000 description 5
- 241000150350 Peribunyaviridae Species 0.000 description 5
- 108010076039 Polyproteins Proteins 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 230000024932 T cell mediated immunity Effects 0.000 description 5
- 108700009124 Transcription Initiation Site Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 108091092328 cellular RNA Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 230000017613 viral reproduction Effects 0.000 description 5
- 230000006490 viral transcription Effects 0.000 description 5
- 239000002023 wood Substances 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000724709 Hepatitis delta virus Species 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 101710199667 Nuclear export protein Proteins 0.000 description 4
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 4
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 4
- 230000006819 RNA synthesis Effects 0.000 description 4
- 240000001068 Thogoto virus Species 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 4
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940031551 inactivated vaccine Drugs 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229960001226 live attenuated influenza Drugs 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000003151 transfection method Methods 0.000 description 4
- 241000712892 Arenaviridae Species 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241000991587 Enterovirus C Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 241000713174 Influenza B virus (B/Ann Arbor/1/1966 [wild- type]) Species 0.000 description 3
- 241001500351 Influenzavirus A Species 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101710144127 Non-structural protein 1 Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 101150103639 PB1 gene Proteins 0.000 description 3
- 208000009341 RNA Virus Infections Diseases 0.000 description 3
- 229940124859 Rotavirus vaccine Drugs 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229940031567 attenuated vaccine Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 208000037799 influenza C Diseases 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 208000005814 piedra Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 201000009862 superficial mycosis Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 102100038284 Cytospin-B Human genes 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000252870 H3N2 subtype Species 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000617996 Human rotavirus Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000713297 Influenza C virus Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101710138767 Non-structural glycoprotein 4 Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 241000702244 Orthoreovirus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000711504 Paramyxoviridae Species 0.000 description 2
- 108091036407 Polyadenylation Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102100031056 Serine protease 57 Human genes 0.000 description 2
- 101710197596 Serine protease 57 Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000710924 Togaviridae Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 108091092330 cytoplasmic RNA Proteins 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 239000013014 purified material Substances 0.000 description 2
- 241000856131 recombinant Influenza A viruses Species 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000776207 Bornaviridae Species 0.000 description 1
- 102100028253 Breast cancer anti-estrogen resistance protein 3 Human genes 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241001264030 Citrus psorosis virus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101710091919 Eukaryotic translation initiation factor 4G Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 241000197306 H1N1 subtype Species 0.000 description 1
- 241000197304 H2N2 subtype Species 0.000 description 1
- 241000252872 H6N1 subtype Species 0.000 description 1
- 241001473386 H9N2 subtype Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000712003 Human respirovirus 3 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000491226 Influenza A virus (A/WSN/1933(H1N1)) Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 1
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 101710144111 Non-structural protein 3 Proteins 0.000 description 1
- 101710144121 Non-structural protein 5 Proteins 0.000 description 1
- 101710144118 Non-structural protein 6 Proteins 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 241001144416 Picornavirales Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000711904 Pneumoviridae Species 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 108010015724 Prephenate Dehydratase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000028391 RNA cap binding Human genes 0.000 description 1
- 108091000106 RNA cap binding Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000702646 Rhesus rotavirus Species 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241001137860 Rotavirus A Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 102100031776 SH2 domain-containing protein 3A Human genes 0.000 description 1
- 102100021798 SH2 domain-containing protein 3C Human genes 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 241000702677 Simian rotavirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000003836 bluetongue Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- MXCPYJZDGPQDRA-UHFFFAOYSA-N dialuminum;2-acetyloxybenzoic acid;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3].CC(=O)OC1=CC=CC=C1C(O)=O MXCPYJZDGPQDRA-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 108010064833 guanylyltransferase Proteins 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 229940033324 influenza A vaccine Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000020130 leben Nutrition 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229930182817 methionine Chemical group 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- UOCLRXFKRLRMKV-UHFFFAOYSA-N trolnitrate phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.[O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O UOCLRXFKRLRMKV-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000004474 valine Chemical group 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/00061—Methods of inactivation or attenuation
- C12N2720/00063—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16261—Methods of inactivation or attenuation
- C12N2760/16263—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18661—Methods of inactivation or attenuation
- C12N2760/18663—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24261—Methods of inactivation or attenuation
- C12N2770/24263—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
- C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20067900P | 2000-04-28 | 2000-04-28 | |
| PCT/US2001/013656 WO2001083794A2 (en) | 2000-04-28 | 2001-04-27 | Dna transfection system for the generation of infectious influenza virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL152426A0 IL152426A0 (en) | 2003-05-29 |
| IL152426A true IL152426A (en) | 2011-07-31 |
Family
ID=22742710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL152426A IL152426A (en) | 2000-04-28 | 2001-04-27 | A DNA transfection system to form an infectious negative-strand RNA virus |
Country Status (25)
Families Citing this family (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8715940B2 (en) | 1999-04-06 | 2014-05-06 | Wisconsin Alumni Research Foundation | Method of making recombinant influenza virus |
| CN100489107C (zh) * | 2000-04-28 | 2009-05-20 | 圣朱德儿童研究医院 | 用于产生感染性流感病毒的dna转染系统 |
| US7465456B2 (en) | 2002-04-26 | 2008-12-16 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
| CN103540568A (zh) * | 2002-04-26 | 2014-01-29 | 米迪缪尼有限公司 | 制备流感病毒的多质粒系统 |
| EP1375512B1 (en) * | 2002-06-20 | 2009-07-22 | Institut Pasteur | Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions |
| DK1375670T3 (da) * | 2002-06-20 | 2013-09-23 | Pasteur Institut | Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger |
| DE10248301A1 (de) * | 2002-10-16 | 2004-04-29 | Philipps-Universität Marburg | Herstellung eines Lebend-Impfstoffes gegen Influenza-Viren |
| US20060110406A1 (en) | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
| KR101251902B1 (ko) | 2003-02-25 | 2013-04-08 | 메디뮨 엘엘씨 | 인플루엔자 백신 조성물의 제조 방법 |
| CA2432738A1 (en) | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| AU2004274860A1 (en) * | 2003-05-28 | 2005-03-31 | Wisconsin Alumni Research Foundation | Recombinant influenza vectors with a polII promoter and ribozymes |
| KR100908757B1 (ko) * | 2003-05-28 | 2009-07-22 | 위스콘신 얼럼나이 리서어치 화운데이션 | 백신 및 유전자 요법을 위한 고 역가 재조합 인플루엔자바이러스 |
| CA2529647C (en) | 2003-06-16 | 2013-08-13 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| US7037707B2 (en) * | 2003-09-04 | 2006-05-02 | St. Jude Children's Research Hospital | Method for generating influenza viruses and vaccines |
| ES2345492T3 (es) * | 2003-12-23 | 2010-09-24 | Medimmune, Llc | Sistema multiplasmido para la produccion del virus de la gripe. |
| EP1722815A1 (en) | 2004-03-09 | 2006-11-22 | Chiron Corporation | Influenza virus vaccines |
| DE102004013335A1 (de) * | 2004-03-17 | 2005-10-13 | TransMIT Gesellschaft für Technologietransfer mbH | Impfstoff gegen Influenza basierend auf Geflügelpestviren |
| EP2811027A1 (en) * | 2004-05-21 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for RSV and PIV vaccines |
| HUE025727T2 (en) | 2004-05-24 | 2016-04-28 | Medimmune Llc | Multi-plasmid system for producing influenza virus |
| EP2530147B1 (en) * | 2004-05-25 | 2014-09-10 | MedImmune, LLC | Influenza hemagglutinin and neuraminidase variants |
| CA2583698C (en) | 2004-10-06 | 2014-12-02 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
| EA200701097A1 (ru) | 2004-11-19 | 2007-10-26 | Висконсин Эламни Рисёч Фаундэйшн | Рекомбинантные векторы вируса гриппа с тандемными транскрипционными единицами |
| US7510719B2 (en) * | 2004-12-08 | 2009-03-31 | Medimmune, Llc | Methods of producing influenza vaccine compositions |
| CA2592120A1 (en) | 2004-12-23 | 2006-07-06 | Medimmune Vaccines, Inc. | Non-tumorigenic mdck cell line for propagating viruses |
| JP5620048B2 (ja) * | 2004-12-24 | 2014-11-05 | アボツト・バイオロジカルズ・ベー・ブイＡｂｂｏｔｔ Ｂｉｏｌｏｇｉｃａｌｓ Ｂ．Ｖ． | インフルエンザウイルスの救済（ｒｅｓｃｕｅ） |
| EP1856271A4 (en) * | 2005-03-08 | 2009-11-18 | Medimmune Vaccines Inc | INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS |
| BRPI0610503B1 (pt) * | 2005-04-21 | 2022-05-31 | University Of Florida Research Foundation | Composições compreendendo vírus influenza, polinucleotídeo isolado, polipeptídeo ou vírus reagrupado, bem como construção de expressão de polinucleotídeo, oligonucleotídeo, micro-organismo transgênico, e métodos para a detecção de um vírus influenza que é capaz de infectar um animal canídeo |
| US7790434B2 (en) * | 2005-06-21 | 2010-09-07 | Medimmune, Llc | Methods and compositions for expressing negative-sense viral RNA in canine cells |
| CA2613283A1 (en) * | 2005-06-21 | 2007-01-04 | Medimmune Vaccines, Inc. | Methods and compositions for expressing a heterologous protease |
| ES2402061T3 (es) | 2005-10-17 | 2013-04-26 | Medimmune, Llc | Método de aumento de la replicación del virus influenza |
| US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| JP5363107B2 (ja) * | 2005-11-04 | 2013-12-11 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | アジュバントを含むスプリットインフルエンザワクチンにおけるｔｈ１／ｔｈ２バランスの変化 |
| NZ567978A (en) | 2005-11-04 | 2011-09-30 | Novartis Vaccines & Diagnostic | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| BRPI0618254A2 (pt) | 2005-11-04 | 2011-08-23 | Novartis Vaccines & Diagnostic | emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido |
| EP2368573A3 (en) | 2005-11-04 | 2013-05-01 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| EP3714900A1 (en) | 2005-11-04 | 2020-09-30 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| US20110180430A1 (en) | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
| BR122019013216B8 (pt) * | 2006-01-27 | 2021-07-27 | Seqirus Uk Ltd | ensaio imunológico para análise de uma vacina contra influenza |
| WO2007110776A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
| AU2012204138B2 (en) * | 2006-03-31 | 2014-02-06 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| JP2009532352A (ja) * | 2006-03-31 | 2009-09-10 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ワクチンのための高力価組み換えインフルエンザ・ウィルス |
| AU2014202470B2 (en) * | 2006-03-31 | 2016-08-04 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| KR101436176B1 (ko) | 2006-04-19 | 2014-09-02 | 메디뮨 엘엘씨 | 개의 세포 내에서 네거티브-센스 바이러스 ｒｎａ를 발현시키기 위한 방법 및 조성물 |
| US9072701B2 (en) | 2006-04-21 | 2015-07-07 | St. Jude Children's Research Hospital | Avian influenza viruses, vaccines, compositions, formulations, and methods |
| US7507411B2 (en) * | 2006-06-23 | 2009-03-24 | University Of Saskatchewan | Attenuated influenza NS1 variants |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| EP2049662A4 (en) * | 2006-07-21 | 2009-12-30 | Medimmune Llc | METHODS AND COMPOSITIONS FOR INCREASING REPLICATION CAPACITY OF A FLU VIRUS |
| KR101586968B1 (ko) * | 2006-08-09 | 2016-01-20 | 메디뮨 엘엘씨 | 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체 |
| EA200970271A1 (ru) | 2006-09-11 | 2010-02-26 | Новартис Аг | Получение вакцин против вируса гриппа без использования куриных эмбрионов |
| KR20140075022A (ko) | 2006-09-15 | 2014-06-18 | 메디뮨 엘엘씨 | 높은 역가로 바이러스 증식을 지원하는 ｍｄｃｋ 세포주 및 이를 이용한 생물반응기 공정 |
| US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| US20130005028A1 (en) * | 2006-12-21 | 2013-01-03 | Smith Larry R | Activation of RIG-I Pathway |
| KR101466326B1 (ko) * | 2007-06-15 | 2014-12-02 | 주식회사 바이오트라이온 | 약독화된 인플루엔자 바이러스 및 이를 포함하는 생백신 |
| CA2690196A1 (en) * | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Influenza b viruses having alterations in the hemaglutinin polypeptide |
| WO2008156778A2 (en) | 2007-06-18 | 2008-12-24 | Tokiko Watanabe | Influenza m2 protein mutant viruses as live influenza attenuated vaccines |
| EP2045323A1 (en) * | 2007-10-05 | 2009-04-08 | Avir Green Hills Biotechnology Research Development Trade Ag | Linear expression constructs for production of influenza virus particles |
| ES2393162T3 (es) | 2007-06-27 | 2012-12-19 | Novartis Ag | Vacunas antigripales con un contenido reducido de aditivos |
| CA2934220C (en) | 2007-10-02 | 2019-11-05 | Theranos, Inc. | Modular point-of-care devices and uses thereof |
| WO2009068870A1 (en) | 2007-11-26 | 2009-06-04 | London School Of Hygiene & Tropical Medicine | Method for producing vaccinal viral strain of a virus of the reoviridae family |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| ES2535101T3 (es) | 2008-03-18 | 2015-05-05 | Novartis Ag | Mejoras en la preparación de antígenos en vacuna de virus de la gripe |
| EP2574344A1 (en) * | 2008-07-11 | 2013-04-03 | MedImmune, LLC | Influenza hemagglutinin and neuraminidase variants |
| WO2010036774A1 (en) | 2008-09-24 | 2010-04-01 | Medimmune, Llc | Methods for purification of viruses |
| EP2233568A1 (en) | 2009-03-19 | 2010-09-29 | Avir Green Hills Biotechnology Research Development Trade AG | Novel method for generation of RNA virus |
| JP2012517416A (ja) | 2009-02-10 | 2012-08-02 | ノバルティス アーゲー | 増加した量のｈ３抗原を含むインフルエンザワクチン |
| AU2010212550B2 (en) | 2009-02-10 | 2016-03-10 | Seqirus UK Limited | Influenza vaccines with reduced amounts of squalene |
| AU2010212547B2 (en) | 2009-02-10 | 2015-03-12 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
| JP5818693B2 (ja) * | 2009-02-12 | 2015-11-18 | メディミューン，エルエルシー | インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体 |
| CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
| CN102548577A (zh) | 2009-04-27 | 2012-07-04 | 诺华有限公司 | 用于抵抗流感的佐剂疫苗 |
| WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
| US9217157B2 (en) | 2009-07-27 | 2015-12-22 | Icahn School Of Medicine At Mount Sinai | Recombinant influenza viruses and uses thereof |
| US8828406B2 (en) | 2009-07-30 | 2014-09-09 | Icahn School Of Medicine At Mount Sinai | Influenza viruses and uses thereof |
| CN104862335A (zh) | 2009-07-31 | 2015-08-26 | 诺华股份有限公司 | 反向遗传系统 |
| SG178904A1 (en) | 2009-09-10 | 2012-04-27 | Novartis Ag | Combination vaccines against respiratory tract diseases |
| EP2491117B2 (en) * | 2009-10-20 | 2017-06-28 | Novartis AG | Improved reverse genetics methods for virus rescue |
| ES2813347T3 (es) | 2009-10-26 | 2021-03-23 | Wisconsin Alumni Res Found | Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero |
| CN102051345B (zh) * | 2009-11-09 | 2013-04-17 | 中国医学科学院医药生物技术研究所 | 一种抗流行性感冒病毒药物的筛选方法 |
| US9701723B2 (en) * | 2010-02-18 | 2017-07-11 | Icahn School Of Medicine At Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| EP3248615A1 (en) | 2010-03-30 | 2017-11-29 | Mount Sinai School of Medicine of New York University | Influenza virus vaccines and uses thereof |
| US20130183740A1 (en) | 2010-06-02 | 2013-07-18 | Avir Green Hills Biotechnology Research Development Trade Ag | Novel method for generation of rna virus |
| AR083533A1 (es) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
| JP5945282B2 (ja) | 2011-01-21 | 2016-07-05 | セラノス， インコーポレイテッド | 試料使用の極大化のためのシステム及び方法 |
| CN103403159B (zh) * | 2011-02-08 | 2018-09-14 | 国立大学法人三重大学 | 用于基因导入的病毒载体的制造方法 |
| US20130189303A1 (en) | 2011-08-02 | 2013-07-25 | Yan Zhou | Recombinant swine influenza virus and uses thereof |
| AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
| EP2747778B1 (en) | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
| US9632102B2 (en) | 2011-09-25 | 2017-04-25 | Theranos, Inc. | Systems and methods for multi-purpose analysis |
| US9664702B2 (en) | 2011-09-25 | 2017-05-30 | Theranos, Inc. | Fluid handling apparatus and configurations |
| US20140170735A1 (en) | 2011-09-25 | 2014-06-19 | Elizabeth A. Holmes | Systems and methods for multi-analysis |
| US8475739B2 (en) | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
| CN108164602A (zh) | 2011-09-20 | 2018-06-15 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| US9810704B2 (en) | 2013-02-18 | 2017-11-07 | Theranos, Inc. | Systems and methods for multi-analysis |
| US10012664B2 (en) | 2011-09-25 | 2018-07-03 | Theranos Ip Company, Llc | Systems and methods for fluid and component handling |
| EP2764015A1 (en) | 2011-10-07 | 2014-08-13 | Medlmmune, LLC | Influenza hemagglutinin variants |
| CA2852857A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
| EP2880154B1 (en) | 2012-08-03 | 2019-05-15 | Sanofi Pasteur SA | Production of infectious influenza viruses |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| CN108641002A (zh) | 2012-12-18 | 2018-10-12 | 西奈山伊坎医学院 | 流感病毒疫苗及其用途 |
| US10401373B1 (en) | 2013-02-18 | 2019-09-03 | Theranos Ip Company, Llc | Systems and methods for analyte testing and laboratory oversight |
| US11008628B1 (en) | 2013-02-18 | 2021-05-18 | Labrador Diagnostics Llc | Systems and methods for analyte testing and laboratory oversight |
| MX360137B (es) | 2013-02-21 | 2018-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento. |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| AU2014290203B2 (en) | 2013-07-15 | 2020-12-24 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs |
| US10422806B1 (en) | 2013-07-25 | 2019-09-24 | Theranos Ip Company, Llc | Methods for improving assays of biological samples |
| HUE051628T2 (hu) | 2013-12-09 | 2021-03-01 | Sangamo Therapeutics Inc | Eljárások és kompozíciók genom-manipulálására |
| CN103757032B (zh) * | 2014-01-28 | 2017-06-06 | 中国人民解放军第三0二医院 | 一种以流感病毒为载体的hcv嵌合疫苗及其制备方法 |
| CA2939942A1 (en) | 2014-02-24 | 2015-08-27 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration |
| US11360107B1 (en) | 2014-02-25 | 2022-06-14 | Labrador Diagnostics Llc | Systems and methods for sample handling |
| AU2015231353B2 (en) | 2014-03-18 | 2020-11-05 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of zinc finger protein expression |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| MA40773A (fr) * | 2014-10-02 | 2017-08-08 | Vertex Pharma | Variants du virus influenza a |
| MA40772A (fr) * | 2014-10-02 | 2017-08-08 | Vertex Pharma | Variants du virus de la grippe a |
| CN104450695B (zh) * | 2014-11-26 | 2017-08-25 | 扬州大学 | A型流感病毒基因pcr扩增引物及其快速克隆方法 |
| US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
| CA2974699A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| KR20180035807A (ko) | 2015-06-26 | 2018-04-06 | 세퀴러스 유케이 리미티드 | 항원적으로 매치된 인플루엔자 백신 |
| US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| HUE060924T2 (hu) | 2015-07-07 | 2023-04-28 | Seqirus Uk Ltd | Influenza elleni hatásosság vizsgálata |
| JP6624736B2 (ja) * | 2015-11-18 | 2019-12-25 | 国立研究開発法人農業・食品産業技術総合研究機構 | インフルエンザウイルス解析装置、インフルエンザウイルス解析方法及びインフルエンザウイルス解析プログラム |
| US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
| AU2017272344B2 (en) | 2016-06-02 | 2022-03-03 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| MX2018015755A (es) | 2016-06-15 | 2019-08-29 | Icahn School Med Mount Sinai | Proteinas de hemaglutinina de virus de influenza y usos de las mismas. |
| WO2018102586A1 (en) | 2016-11-30 | 2018-06-07 | Merial, Inc. | Attenuated swine influenza vaccines and methods of making and use thereof |
| EP3606555A4 (en) | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
| US11197926B2 (en) | 2017-10-25 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| US12364746B2 (en) | 2018-06-21 | 2025-07-22 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| WO2020033527A2 (en) | 2018-08-07 | 2020-02-13 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| WO2020041311A1 (en) | 2018-08-20 | 2020-02-27 | Wisconsin Alumni Research Foundation | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein |
| WO2020167432A2 (en) | 2019-01-23 | 2020-08-20 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| WO2021150874A1 (en) | 2020-01-24 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized na |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| WO2022051327A1 (en) * | 2020-09-02 | 2022-03-10 | St. Jude Children's Research Hospital, Inc. | Hemagglutinin modifications for improved influenza vaccine production |
| WO2022056398A1 (en) * | 2020-09-11 | 2022-03-17 | University Of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for prevention and treatment of influenza infections |
| KR102614346B1 (ko) | 2020-12-14 | 2023-12-14 | 서울대학교산학협력단 | Ｈ5ｎ6 재조합 인플루엔자 바이러스, 이의 제조용 조성물, 및 이를 포함하는 백신 조성물 |
| CN121039284A (zh) | 2023-03-22 | 2025-11-28 | 兰蒂迪克有限公司 | 表达构建体 |
| WO2025019631A1 (en) | 2023-07-19 | 2025-01-23 | Icahn School Of Medicine At Mount Sinai | Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof |
| WO2025072889A1 (en) * | 2023-09-28 | 2025-04-03 | E & E Bioclub Llc | Helper-free rescue system for negative-strand rna viruses |
| WO2025075855A1 (en) * | 2023-10-03 | 2025-04-10 | St. Jude Children's Research Hospital, Inc. | Reverse genetics vector and associated method of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3992522A (en) * | 1973-01-24 | 1976-11-16 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Temperature-sensitive recombinant mutant viruses and a process for producing same |
| US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
| US5840520A (en) | 1989-08-28 | 1998-11-24 | Aviron | Recombinant negative strand RNA virus expression systems |
| US5854037A (en) | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
| US5786199A (en) | 1989-08-28 | 1998-07-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
| EP0808361A4 (en) | 1994-11-16 | 2001-07-18 | St Jude Childrens Res Hospital | Novel replication process |
| DE122008000058I1 (de) | 1999-04-06 | 2009-05-07 | Wisconsin Alumni Res Found | Rekombinante influenzaviren zur vakzinherstellung und gentherapie |
| CN100489107C (zh) * | 2000-04-28 | 2009-05-20 | 圣朱德儿童研究医院 | 用于产生感染性流感病毒的dna转染系统 |
| US7465456B2 (en) * | 2002-04-26 | 2008-12-16 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
| CN103540568A (zh) | 2002-04-26 | 2014-01-29 | 米迪缪尼有限公司 | 制备流感病毒的多质粒系统 |
| ES2345492T3 (es) | 2003-12-23 | 2010-09-24 | Medimmune, Llc | Sistema multiplasmido para la produccion del virus de la gripe. |
-
2001
- 2001-04-27 CN CNB018101739A patent/CN100489107C/zh not_active Expired - Lifetime
- 2001-04-27 EP EP01932704A patent/EP1317559B1/en not_active Expired - Lifetime
- 2001-04-27 PT PT01932704T patent/PT1317559E/pt unknown
- 2001-04-27 UA UA2002108499A patent/UA84254C2/ru unknown
- 2001-04-27 JP JP2001580401A patent/JP2004500842A/ja not_active Withdrawn
- 2001-04-27 KR KR1020077013242A patent/KR100848719B1/ko not_active Expired - Lifetime
- 2001-04-27 MX MXPA02010642A patent/MXPA02010642A/es active IP Right Grant
- 2001-04-27 DE DE201112100039 patent/DE122011100039I1/de active Pending
- 2001-04-27 NZ NZ521840A patent/NZ521840A/en not_active IP Right Cessation
- 2001-04-27 HU HU0303036A patent/HU229101B1/hu unknown
- 2001-04-27 DE DE60137345T patent/DE60137345D1/de not_active Expired - Lifetime
- 2001-04-27 AT AT01932704T patent/ATE420189T1/de active
- 2001-04-27 KR KR1020027014311A patent/KR100862758B1/ko not_active Expired - Lifetime
- 2001-04-27 EA EA200201164A patent/EA006311B1/ru not_active IP Right Cessation
- 2001-04-27 DK DK01932704T patent/DK1317559T3/da active
- 2001-04-27 CN CN2009101302370A patent/CN101580849B/zh not_active Expired - Lifetime
- 2001-04-27 BR BRPI0110607-4 patent/BRPI0110607B8/pt not_active IP Right Cessation
- 2001-04-27 AU AU2001259211A patent/AU2001259211B2/en not_active Expired
- 2001-04-27 WO PCT/US2001/013656 patent/WO2001083794A2/en not_active Ceased
- 2001-04-27 EP EP08019287A patent/EP2085468A1/en not_active Withdrawn
- 2001-04-27 CA CA2406100A patent/CA2406100C/en not_active Expired - Lifetime
- 2001-04-27 PL PL366064A patent/PL205955B1/pl unknown
- 2001-04-27 US US09/844,517 patent/US6951754B2/en not_active Expired - Lifetime
- 2001-04-27 IL IL152426A patent/IL152426A/en active IP Right Grant
- 2001-04-27 SI SI200130900T patent/SI1317559T1/sl unknown
- 2001-04-27 AU AU5921101A patent/AU5921101A/xx active Pending
- 2001-04-27 ES ES01932704T patent/ES2319864T3/es not_active Expired - Lifetime
-
2002
- 2002-10-08 ZA ZA200208065A patent/ZA200208065B/en unknown
- 2002-10-28 NO NO20025171A patent/NO332080B1/no not_active IP Right Cessation
-
2005
- 2005-03-29 US US11/093,430 patent/US7312064B2/en not_active Expired - Lifetime
-
2006
- 2006-10-12 AU AU2006228054A patent/AU2006228054B2/en not_active Expired
-
2007
- 2007-10-31 US US11/980,753 patent/US7972843B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/980,762 patent/US20080311149A1/en not_active Abandoned
- 2007-10-31 US US11/980,761 patent/US20080311148A1/en not_active Abandoned
-
2009
- 2009-01-28 CY CY20091100106T patent/CY1108735T1/el unknown
- 2009-11-24 JP JP2009266560A patent/JP5745758B2/ja not_active Expired - Lifetime
-
2011
- 2011-06-01 US US13/150,426 patent/US8309099B2/en not_active Expired - Fee Related
-
2013
- 2013-01-11 JP JP2013003472A patent/JP5837891B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1317559B1 (en) | Dna transfection system for the generation of infectious negative strand rna virus | |
| IL151426A (en) | Compounds of 4,3 - Dihydro - H1 - Pyrimido [D - 4, 5] Pyrimidine - 2 - On-converted at position 1.5 and their use in the preparation of drugs for the treatment of diseases caused by 38P / CSBP kinase | |
| AU2001259211A1 (en) | DNA transfection system for the generation of infectious influenza virus | |
| US9238825B2 (en) | Multi plasmid system for the production of influenza virus | |
| US20140220075A1 (en) | Multi plasmid system for the production of influenza virus | |
| NZ536260A (en) | Development of a multi-plasmid pol I - pol II based system for the generation of infectious influenza RNA viruses from cloned DNA | |
| HK1055992B (en) | Dna transfection system for the generation of infectious negative strand rna virus | |
| CA2712368A1 (en) | Dna transfection system for the generation of infectious influenza virus | |
| CA2827114A1 (en) | Multi plasmid system for the production of influenza virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |